Key facts
- This page summarizes Alejandro Galindo's Form 4 filing for MANNKIND CORP (MNKD).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Aug 2022, 21:00.
Alejandro Galindo - 22 Aug 2022 Form 4 Insider Report for MANNKIND CORP (MNKD)
- Reporting relationship
- EVP Endocrine Business Unit
- Issuer ticker
- MNKD
- Reported as of
- 22 Aug 2022
- Net transaction value
- -$17,771
- SEC form
- 4
- Accepted by SEC
- 23 Aug 2022, 21:00:24 UTC
- Prior SEC filing
- 24 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alejandro Galindo
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alejandro Galindo filed Form 4 for MANNKIND CORP (MNKD) on 23 Aug 2022.
Change
- Previous filing in this sequence was filed on 24 Aug 2022.
- Current net transaction value: -$17,771.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MNKD
transaction
Common Stock, $0.01 Par Value
Sale
- Transaction value
- $17,713
- Shares
- -4,600
- Change %
- -0.59%
- Price
- $3.85
- Shares after
- 777,090
- Date
- 22 Aug 2022
- Ownership
- Direct
MNKD
transaction
Common Stock, $0.01 Par Value
Sale
- Transaction value
- $57.6
- Shares
- -15
- Change %
- -0%
- Price
- $3.84
- Shares after
- 777,075
- Date
- 22 Aug 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.